- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07918261
Evaluation of Fisetin to Reduce Systemic Senescence
Evaluation of Fisetin to Reduce Systemic Senescence Indices: A Randomized Controlled Dosing Equivalence Study
This is a prospective, randomized clinical trial to evaluate the ability of the supplement, Fisetin, to safely reduce systemic senescence (aging) indices assessed in peripheral blood.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a prospective, randomized clinical trial designed to examine the effect of two different Fisetin dosing schedules on peripheral blood cells and biomarkers related to aging as well as the occurrence of side effects. The purpose of this study is to evaluate the ability of the supplement, Fisetin, to safely reduce systemic senescence (aging) indices assessed in peripheral blood. 96 healthy volunteers will be randomized into one of two arms (1:1). Group 1 - n= 48: Fisetin Daily Dosing; Group 2 - n=48: Fisetin Bolus Dosing.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Colorado
-
Vail, Colorado, United States, 81657
- Steadman Philippon Research Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults ≥55 years of age;
- Capacity to personally give informed consent (consent via legally authorized representative will not be accepted);
- Willing to comply with all study procedures and assessments.
Exclusion Criteria:
-
Within 2 years of signing informed consent history of active blood disorders (i.e., DVTs, chronic blood clotting, hemophilia, leukemia, myeloma, etc.); or active malignancy of any type or history of a malignancy (with the exception of Subjects with a history of treated basal or squamous cell carcinoma);
-
Females who are nursing a child, are pregnant, or are planning to become pregnant during drug dosing;
-
Males who do not wish to abstain from sex with women of childbearing potential without use of contraceptive protection by either party during drug dosing;
-
Any significant illness within the last 30 days requiring clinical care, and/or any medications, medical condition, including findings in medical history or in the baseline assessments that, in the opinion of the Principal Clinical Investigator or the screening clinician, constitutes a risk or contraindication for participation in the study or that could interfere with the study conduct, endpoint evaluation, or prevent the subject from fully participating in all aspects of the study;
-
Allergy to any active or inactive ingredient of Fisetin, and/or taking medication with known Fisetin interaction;
-
Subjects with any of the following drug/medication statuses:
- Taking medications that affect insulin activity, including Metformin or Acarbose, within one week of signing informed consent;
- Currently taking Warfarin or related anticoagulants;
- Currently taking Lithium;
- Senolytic agents taken within the past 3 months and are not willing to discontinue these medications through the duration of the study, including: Fisetin, Quercetin, Luteolin, Dasatinib, Piperlongumine, or Navitoclax;
- Taking drugs that induce significant cellular stress and are not willing to discontinue these medications through the duration of the study, including alkylating agents, anthracyclines, platins, and other chemotherapy drugs;
- Taking the following drugs if they cannot be held (per the Principal Investigator) for at least 2 days before and during administration of Fisetin: cyclosporine, tacrolimus, repaglinide, and bosentan;
- Taking a glucocorticoid within 1 month of signing informed consent;
- Currently taking phenytoin or nateglinide;
-
PHQ-9 - Patient Health Questionnaire - total score exceeds 9;
-
Inability to tolerate oral medication;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Fisetin (daily dosing)
A single Fisetin 100mg capsule will be taken daily for 60 days. |
Oral Fisetin 100mg capsule
Other Names:
|
|
Experimental: Fisetin (bolus dosing)
Fisetin 100 mg capsules (~20 mg/ kg/ day) will be administered orally for two consecutive days (days 1 and 2) followed by 28 days off. This cycle of 2 dosing days followed by 28 days off will repeat for a total of 2 cycles, or 4 dosing days total. Dosing days will occur on days 1&2, and 31&32. |
Oral Fisetin 100mg capsule, dosed at 20 mg/kg
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline in levels of senescent PBMCs (total and specific PBMC subsets such as T-Cells)
Time Frame: Baseline, Visit 4 (45 days)
|
Cell types measured via flow cytometry and analyzed via immunophenotype and senescent panels. |
Baseline, Visit 4 (45 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline in levels of senescent PBMCs (total and specific PBMC subsets such as T-Cells)
Time Frame: Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 5 (60 days)
|
Cell types measured via flow cytometry and analyzed via immunophenotype and senescent panels. |
Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 5 (60 days)
|
|
Change from baseline in senescence-related serum biomarkers
Time Frame: Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)
|
Concentrations of proteins related to senescence will be analyzed using multiplex immunoassays and ELISA from serum/plasma. |
Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)
|
|
Number of participants experiencing one or more treatment-emergent adverse events
Time Frame: From date of study drug dosing until the end of the study, an average of 2 months
|
Number of participants experiencing one or more treatment-emergent adverse events |
From date of study drug dosing until the end of the study, an average of 2 months
|
|
Perturbations in senescent PBMC values
Time Frame: Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)
|
Cell types measured via flow cytometry and analyzed via immunophenotype and senescent panels. |
Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)
|
|
Perturbations in senescent serum/plasma biomarkers values
Time Frame: Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)
|
The variability over visits of serum/plasma concentrations of proteins related to senescence will be assessed using multiplex immunoassay and ELISA. |
Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Johnny Huard, PhD, Steadman Philippon Research Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022-154
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.